Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19193303 | Skin Care Compositions and Methods of Using the Same | April 2025 | September 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19098553 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | April 2025 | August 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18824970 | POLYPEPTIDE WITH ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITY, AND PREPARATION METHOD AND USE THEREOF | September 2024 | March 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18602421 | PHOTOSTABILIZED COMPOSITIONS AND A METHOD FOR STABILIZING PHOTOSENSITIVE COMPONENTS | March 2024 | February 2026 | Allow | 24 | 2 | 1 | Yes | No |
| 18594290 | SKIN CARE PRODUCT WITH PROTEIN MATRIX | March 2024 | October 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18417206 | METHODS OF TREATING ALZHEIMERS DISEASE | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18408052 | ACYLATED GLUCAGON ANALOGUES | January 2024 | July 2025 | Allow | 18 | 1 | 0 | No | No |
| 18394401 | INSULIN LIKE GROWTH FACTOR BINDING PROTEIN BIOACTIVE PEPTIDE FRAGMENTS | December 2023 | May 2025 | Allow | 17 | 1 | 1 | No | No |
| 18541847 | COMPOUNDS FOR USE IN INDUCING MYOCARDIAL PERFUSION RECOVERY | December 2023 | February 2026 | Abandon | 26 | 1 | 1 | No | No |
| 18527006 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | December 2023 | April 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18520428 | ODORANT-BINDING PROTEIN COMPOSITIONS, METHODS AND USES THEREOF | November 2023 | October 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18387450 | DIIODOHYDROXYQUINOLINE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | November 2023 | November 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18482589 | VEGF TRAPS AND MINI-TRAPS AND METHODS FOR TREATING OCULAR DISORDERS AND CANCER | October 2023 | March 2025 | Allow | 18 | 1 | 1 | No | No |
| 18464024 | COMPOSITIONS AND METHODS OF USE FOR TREATMENT OR IMPROVEMENT OF THE CONDITION AND APPEARANCE OF SKIN | September 2023 | August 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18235592 | METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES | August 2023 | February 2026 | Abandon | 30 | 1 | 0 | No | No |
| 18446712 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME | August 2023 | July 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18447049 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME | August 2023 | July 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18363178 | MENTSH ANALOGS AS THERAPEUTICS FOR DIABETES, OBESITY, AND THEIR ASSOCIATED DISEASES AND COMPLICATIONS | August 2023 | January 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18356280 | CER-001 THERAPY FOR TREATING KIDNEY DISEASE | July 2023 | March 2025 | Allow | 20 | 1 | 1 | No | No |
| 18220940 | CELL PENETRATING PEPTIDES THAT INHIBIT IRF5 NUCLEAR LOCALIZATION | July 2023 | August 2024 | Allow | 13 | 1 | 1 | No | No |
| 18346365 | PHARMACEUTICALS AND DOSING MEANS FOR HUMAN AGING REVERSAL | July 2023 | December 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 18345601 | PEPTIDE CONJUGATES | June 2023 | January 2026 | Abandon | 30 | 0 | 1 | No | No |
| 18341320 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | June 2023 | February 2026 | Allow | 32 | 2 | 1 | Yes | No |
| 18308908 | PEPTIDE EXHIBITING WRINKLE-IMPROVING ACTIVITY AND USES THEREOF | April 2023 | June 2024 | Allow | 14 | 0 | 1 | No | No |
| 18308985 | PEPTIDE EXHIBITING WRINKLE-IMPROVING ACTIVITY AND USES THEREOF | April 2023 | April 2024 | Allow | 12 | 0 | 1 | No | No |
| 18172867 | Wet Adhesive Peptides | February 2023 | October 2023 | Allow | 8 | 1 | 0 | No | No |
| 18172787 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME | February 2023 | August 2024 | Allow | 17 | 2 | 1 | No | No |
| 18158642 | PEPTIDE HAVING CYTOPROTECTIVE EFFECT AGAINST ENVIRONMENTAL POLLUTANT AND USE THEREOF | January 2023 | July 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 18151166 | MYOKINES FOR TREATING CELL PROLIFERATIVE AND METABOLIC DISEASES AND DISORDERS | January 2023 | November 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 18003127 | FRAGRANCE RELEASE MECHANISM, METHOD AND USES THEREOF | December 2022 | November 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 18068387 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | December 2022 | May 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 18078645 | PREVENTING CYTOKINE RELEASE SYNDROME | December 2022 | November 2025 | Allow | 35 | 2 | 1 | No | No |
| 18076033 | 14-3-3 TARGETING PEPTIDES FOR CANCER TREATMENT | December 2022 | June 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17927390 | THERAPEUTIC COMPOSITION AND METHOD FOR TREATING CORONAVIRUS INFECTION | November 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17998237 | VIMENTIN AND FRAGMENTS OR DERIVATIVES THEREOF FOR CORONAVIRUS TREATMENT AND PREVENTION | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18052064 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL AND OTHER DISORDERS | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17948146 | PEPTIDES DERIVED FROM MELANOMA-ASSOCIATED ANTIGEN C2 (MAGEC2) AND USES THEREOF | September 2022 | December 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17933028 | SELECTIVE PEPTIDE ANTAGONISTS | September 2022 | September 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17941888 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | September 2022 | June 2024 | Abandon | 21 | 2 | 0 | Yes | No |
| 17908075 | METHODS AND COMPOSITIONS FOR TREATING MUSCLE ATROPHY | August 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17802676 | METHOD OF ENHANCING AQUEOUS HUMOR OUTFLOW AND REDUCING INTRAOCULAR PRESSURE | August 2022 | July 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17822217 | Methods and Compositions for Use of a Chemokine Receptor Antagonist Peptide to Treat Addiction, Substance Abuse Disorders or Symptoms Thereof | August 2022 | December 2024 | Allow | 27 | 1 | 1 | No | No |
| 17821421 | PEA-DERIVED PEPTIDE WITH MUSCLE-BUILDING EFFECT AND PREPARATION METHOD THEREOF, AND DRUG AND USE | August 2022 | January 2024 | Allow | 17 | 1 | 1 | No | No |
| 17891946 | A HIGH-PURITY ADRENOCORTICOTROPIC HORMONE ANALOGUE AND A LARGE-SCALE PREPARATION METHOD THEREOF | August 2022 | August 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17877378 | COMPOSITIONS AND METHODS FOR ENHANCING NEURO-REPAIR | July 2022 | August 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17759225 | TREATMENT OF CARDIAC REMODELLING | July 2022 | August 2025 | Abandon | 37 | 2 | 1 | Yes | No |
| 17869284 | COMPOSITIONS AND METHODS FOR TREATMENT OF FUNGAL INFECTIONS | July 2022 | July 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17792844 | ARGININE ASPARTATE-CONTAINING COMPOSITION FOR SUPPRESSING OLD PERSON SMELL | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17811748 | C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia in Children | July 2022 | October 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17791270 | PEPTIDE-CONTAINING COMPOSITION FOR USE FOR TREATING NEOPLASTIC LESIONS | July 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17791341 | FGF-21 CONJUGATE FORMULATIONS | July 2022 | February 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17853296 | Calcium Channel 3.2 Inhibitory Peptides and Uses Thereof | June 2022 | March 2025 | Allow | 33 | 3 | 1 | Yes | No |
| 17788738 | TRIPLE AGONIST FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR, GLUCAGON RECEPTOR, AND GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR | June 2022 | February 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17847275 | METHOD OF TREATING PARKINSON'S DISEASE WITH INTRANASAL DELIVERY OF INSULIN AND GLUTATHIONE | June 2022 | October 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17847272 | METHOD OF TREATING PARKINSON'S DISEASE WITH INTRANASAL DELIVERY OF INSULIN AND GLUTATHIONE | June 2022 | October 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17835278 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME | June 2022 | August 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17757020 | COMPOSITION COMPRISING P53-ACTIVATING PEPTIDE | June 2022 | April 2025 | Allow | 34 | 0 | 0 | No | No |
| 17835770 | CYCLIC PEPTIDE ANALOGS OF MELANOCORTIN AND AMANITIN AND METHODS OF MAKING SUCH | June 2022 | October 2023 | Allow | 17 | 0 | 1 | Yes | No |
| 17827700 | COMPOSITION AND METHOD FOR HIP1-TARGETING INHIBITOR COMPOUNDS | May 2022 | January 2026 | Allow | 44 | 3 | 2 | Yes | No |
| 17779307 | PEPTIDES AND COMPOSITIONS FOR INHIBITING HAIR GROWTH | May 2022 | June 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17664232 | ASSOCIATION OF N-ACETYLCYSTEINE AND COLISTIN FOR USE IN BACTERIAL INFECTIONS | May 2022 | June 2024 | Allow | 25 | 2 | 1 | No | No |
| 17777464 | COMPOSITION FOR DIAGNOSING, PREVENTING, OR TREATING COGNITIVE DYSFUNCTION COMPRISING COTL1 AS ACTIVE INGREDIENT | May 2022 | September 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17776749 | MEDICAL COMPOSITION FOR TREATING CARDIAC WASTING AND CACHEXIA | May 2022 | October 2024 | Allow | 29 | 1 | 1 | No | No |
| 17776375 | LYSIN-ANTIMICROBIAL PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTS, LYSINS, ISOLATED POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF | May 2022 | October 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17740743 | TEVERELIX-TFA COMPOSITION | May 2022 | April 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17736261 | CONJUGATE OF ISOTRETINOIN AND PEPTIDE | May 2022 | April 2024 | Allow | 23 | 1 | 1 | No | No |
| 17734653 | COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTIONS | May 2022 | August 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17772756 | KERATIN BD-10, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | April 2022 | June 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17724091 | VARIANT FORMS OF URATE OXIDASE AND USE THEREOF | April 2022 | May 2023 | Allow | 13 | 1 | 0 | No | No |
| 17769990 | HAIR GROWTH AGENT | April 2022 | January 2026 | Abandon | 45 | 2 | 0 | No | No |
| 17720601 | METHODS OF MAKING STABLE SILK FIBROIN FORMULATIONS | April 2022 | July 2024 | Allow | 27 | 3 | 1 | Yes | No |
| 17762817 | ANTI-AGING COMPOSITIONS AND METHODS OF USE THEREOF | March 2022 | June 2025 | Allow | 39 | 1 | 1 | No | No |
| 17762225 | ORAL DELIVERY SYSTEM | March 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17761496 | PEPTIDE-CONJUGATED PRODRUGS | March 2022 | January 2026 | Allow | 46 | 2 | 1 | Yes | No |
| 17651675 | Methods of Enhancing Protection Against Organ and Vascular Injury, Hematopoietic Recovery and Survival in Response to Total Body Radiation/Chemical Exposure | February 2022 | June 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17635962 | FUSED POLYPEPTIDE WITH MULTIFUNCTIONAL ACTIVITIES AND USE THEREOF | February 2022 | May 2025 | Allow | 39 | 2 | 0 | Yes | No |
| 17670300 | CELL HYDROLYSATE COMPOSITION FROM CULTIVATED CELLS AND APPLICATIONS THEREOF | February 2022 | April 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17670288 | CELL HYDROLYSATE COMPOSITION FROM CULTIVATED CELLS AND APPLICATIONS THEREOF | February 2022 | June 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17650386 | SPRAY DRIED FORMULATION OF A CHOLERA TOXIN B SUBUNIT VARIANT | February 2022 | February 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17633147 | ANTI-ISCHEMIC COMPOSITIONS | February 2022 | July 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17631533 | PEPTIDES AS INHIBITORS OF FIBROTIC MATRIX ACCUMULATION | January 2022 | July 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17586185 | INSULIN LIKE GROWTH FACTOR BINDING PROTEIN BIOACTIVE PEPTIDE FRAGMENTS | January 2022 | August 2023 | Allow | 19 | 1 | 1 | No | No |
| 17584468 | METHOD OF TREATING PARKINSON'S DISEASE WITH INTRANASAL DELIVERY OF INSULIN AND GLUTATHIONE | January 2022 | July 2023 | Allow | 18 | 3 | 1 | Yes | No |
| 17643251 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | December 2021 | March 2024 | Allow | 27 | 1 | 1 | No | No |
| 17542134 | NEW DOSAGE REGIMEN FOR INHALED VASOACTIVE INTESTINAL POLYPEPTIDE | December 2021 | December 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17539132 | COMPOSITIONS AND METHODS OF USE FOR TREATMENT OR IMPROVEMENT OF THE CONDITION AND APPEARANCE OF SKIN | November 2021 | November 2023 | Abandon | 24 | 1 | 1 | No | No |
| 17533038 | PEPTIDES INHIBITING KLK1, KLK4, OR KLK4 AND KLK8 | November 2021 | August 2023 | Allow | 20 | 1 | 1 | Yes | No |
| 17525793 | ANGIO-3 FOR TREATMENT OF RETINAL ANGIOGENIC DISEASES | November 2021 | November 2023 | Abandon | 24 | 1 | 1 | No | No |
| 17610361 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE | November 2021 | October 2024 | Abandon | 35 | 0 | 1 | Yes | No |
| 17514906 | LYOPHILIZED RECOMBINANT VWF FORMULATIONS | October 2021 | March 2026 | Allow | 52 | 4 | 1 | No | No |
| 17607235 | PAR2 MODULATION AND METHODS THEREOF | October 2021 | November 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17512573 | H3.3 CTL PEPTIDES AND USES THEREOF | October 2021 | July 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17605723 | PEPTIDES INHIBITING ANDROGEN RECEPTOR ACTIVITY, AND COSMETICS COMPOSITION USING SAME | October 2021 | October 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17506206 | PEPTIDE COACERVATES AND METHODS OF USE THEREOF | October 2021 | March 2024 | Allow | 29 | 2 | 1 | No | No |
| 17496810 | COMPOSITE POLYPEPTIDE HAVING A METAL BINDING MOTIF AND MOLECULAR CONSTRUCT COMPRISING THE SAME | October 2021 | October 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17496986 | METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED CONDITIONS | October 2021 | August 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17602729 | NOVEL PSMA SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT | October 2021 | December 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17599034 | LIPOCALIN MUTEIN FOR TREATMENT OF ASTHMA | September 2021 | February 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17442682 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE | September 2021 | September 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17482696 | PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID AND CARNOSINE AND RELATIVE USE | September 2021 | November 2024 | Allow | 38 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HA, JULIE.
With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HA, JULIE works in Art Unit 1654 and has examined 929 patent applications in our dataset. With an allowance rate of 65.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.
Examiner HA, JULIE's allowance rate of 65.9% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by HA, JULIE receive 1.40 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HA, JULIE is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +57.8% benefit to allowance rate for applications examined by HA, JULIE. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 35.8% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 54.1% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 72.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 84.0% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 11.9% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.6% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.